# Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

> **NCT04262687** · PHASE2 · UNKNOWN · sponsor: **Federation Francophone de Cancerologie Digestive** · enrollment: 55 (estimated)

## Conditions studied

- Colorectal Cancer Metastatic
- High Immune Infiltrate
- Microsatellite Stable

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Bevacizumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04262687
- **Lead sponsor:** Federation Francophone de Cancerologie Digestive
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-06
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2023-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04262687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04262687, "Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT04262687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*